Glial Cell Reprogramming via PTB Knockdown for Neuron Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods struggle to efficiently convert non-neuronal cells, such as glial cells, into functional neurons in vivo, particularly in specific locations like the retina and striatum, for treating neurodegenerative diseases.
Innovation Solution
Utilizing CRISPR/Cas effector proteins, like Cas13d, CasRx, Cas13c, and Cas13f, combined with guide RNAs targeting PTB mRNA, to suppress PTB expression in glial cells, enabling them to reprogram into functional neurons like retinal ganglion cells or dopaminergic neurons, using AAV vectors for delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional cell replacement or trans-differentiation methods are used, then neurodegenerative diseases can be treated, but the conversion efficiency of glial cells to functional neurons in vivo is insufficient
Solution Approach 1:
The patent uses CRISPR/Cas13d system to change the expression level of PTB protein parameter in glial cells, thereby inducing trans-differentiation into neurons. By targeting PTB mRNA with specific gRNAs, the system achieves precise control over protein levels to drive cell fate conversion while maintaining functional integration
Solution Approach 2:
The patent employs AAV vectors as intermediaries to deliver CRISPR/Cas13d components to specific brain regions. The viral vector system enables efficient in vivo delivery of the gene editing machinery to glial cells, facilitating high-conversion efficiency while ensuring proper spatial and temporal expression control
2Productivity
If CRISPR/Cas13d system is used to suppress PTB expression, then glial cells can be efficiently converted to neurons, but the complexity of the gene editing system increases
Solution Approach 1:
The patent merges multiple functional components (Cas13d protein, gRNA, and AAV vector system) into a unified delivery platform. By combining these elements into a single AAV-based gene editing system, the patent simplifies the overall approach while achieving high conversion efficiency through coordinated action of all components
Solution Approach 2:
The CRISPR/Cas13d system described in the patent has universal applicability across different brain regions and glial cell types. The same basic system architecture can be adapted to convert various glial cells (astrocytes, oligodendrocytes, microglia) into different neuronal phenotypes by simply changing the gRNA target specificity, thereby reducing overall system complexity through reuse of the core platform
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach efficiently converts at least 10-30% of glial cells into functional neurons, effectively replenishing degenerated neurons and restoring neural function, as demonstrated by improved visual and motor functions in animal models.
Implementation Method 1
PTB expression or activity is suppressed by expressing in said glial cell a CRISPR/Cas effector protein and a guide RNA (gRNA) complementary to a PTB mRNA
Implementation Method 2
the expression vector comprises a viral vector. In certain embodiments, the viral vector is selected from the group consisting of: an adeno-associated virus (AAV) vector, an adenovirus vector, a lentivirus vector, a retrovirus vector
Data Source
AI summary
Methods and compositions for treating certain neurodegenerative diseases are provided. The method uses in vivo conversion of gilal cells to neurons by PTB and optionally nPTB knock down via CRISPR/Cas delivered by viral vectors (e.g., AAV vector). Examples of the neurodegenerative diseases include RGC loss-related degenerative disease and Parkinson's Disease,